Micropore Technologies and Labman Launch Pathfinder for Nucleic Acid Therapeutics
Micropore Technologies and Labman have developed Pathfinder™, an automated platform enhancing nucleic acid therapeutic formulation. This innovation is pivotal for increasing efficiency in research and manufacturing, addressing market demands for sustainable high-throughput solutions.
Theia Market Signal Identification - AI Assisted
Micropore Technologies and Labman have collaborated to create Pathfinder™, a compact automation system aimed at improving the formulation of nucleic acid therapeutics, vaccines, and nanoparticles. This device combines Micropore's AXF™mini technology with Labman's automation expertise, allowing for high-throughput screening of up to 96 samples in under sixty seconds with minimal waste.
Pathfinder features two operational modes: Discover, which requires as little as 400 μL of waste, and Develop, scaling up to 250 mL for clinical production. The partnership is extending to the Horizon™ system, funded by Innovate UK, designed for GMP-ready manufacturing with flow rates of 3-450 mL/min. The advancements from these systems are expected to significantly enhance the speed of transitioning research to clinical applications.
Comments